Jeff Terkowitz

About Jeff Terkowitz

Jeff Terkowitz is the Vice President of Product for Inspire. Before Inspire, Jeff was Director at Avalere Health focusing on Medicare data solutions. A graduate of Cornell University, Jeff specializes in health policy analysis and data-driven research to inform business strategy.
Vice President of Product

Top 5 Ways Online Patient Communities Can Reduce the Cost of Clinical Trials

Top 5 Ways Online Patient Communities Can Reduce the Cost of Clinical Trials By Jeff Terkowitz Trying to rein in clinical trial costs? You’re not alone. A JAMA research study of 138 trials for novel therapeutics found that clinical trial costs ranged from less than $5 million to $346.8 million, with a [...]

Recruiting Rare and Oncological Patients? Top Pharma Turns to Inspire

Recruiting Rare and Oncological Patients? Top Pharma Turns to Inspire By Jeff Terkowitz Did you know that 80 percent of Inspire’s members agreed to receive information from Inspire about clinical trials? That’s about 1.6 million members with conditions in oncology, rare diseases, autoimmune disorders and chronic conditions who want to know if [...]

Patients Discuss and Debate the Medical Outcomes from Generic Formulations

Patients Discuss and Debate the Medical Outcomes from Generic Formulations By Jeff Terkowitz When mature products face the introduction of generics, patients are often considering, or asked to consider, switching their medications. At that transition, there is a high need for Real World Data documenting patient experiences. What happens to medical outcomes [...]

Patient Support Needs Patient Input

Patient Support Needs Patient Input By Jeff Terkowitz Here’s a patient support marketing scenario: You’re in charge of creating a patient support program that reaches out past the point of prescription. The drug you’re supporting is a molecule that requires long-term adherence to be effective. You’re looking for end-to-end results. You’re undoubtedly [...]

How is COVID-19 Impacting Patients and the Life Science Industry?

How is COVID-19 Impacting Patients and the Life Science Industry? By Jeff Terkowitz As a virtual business, Inspire has a head start in dealing with social distancing and COVID-19. Many of our employees work virtually. Our patient and caregiver members have always communicated virtually and during this time are actively engaged in [...]

Patients Should Inform Clinical Trial Development: Inspire Webinar 1 2020

Patients Should Inform Clinical Trial Development: Inspire Webinar 1 2020 By Jeff Terkowitz Lesley Gosden, a patient and patient advocate with Parkinson's disease, gave the patient keynote speech opening “Patients As Partners Europe,” held January 27-28.1 She described her experience in the GDNF study, which involved the surgical implantation of a port [...]

Everything Your Organization Needs in One Place: Inspire Products

Everything Your Organization Needs in One Place: Inspire Products Inspire has four product lines available to address the needs of the life science industry and other healthcare organizations, like hospitals and clinics. Thousands of patients within Inspire’s communities are interested in and actively looking for opportunities to [...]

Patients MacGyvering: a resource for device and equipment manufacturers

Patients MacGyvering: a resource for device and equipment manufacturers To solve problems that patients actually have is a challenge. Companies miss opportunities when blindly offering patients what people other than patients say they need. When medical device or equipment manufacturers are looking for ideas or trying to think of ways to improve [...]

Inspire posts forward medical research in adverse drug reactions, new study shows

Inspire posts forward medical research in adverse drug reactions, new study shows Over 2 million injuries, hospitalizations and deaths in the US each year are associated with post-approval adverse drug reactions (ADRs).1 The usual method of gathering ADR data is through provider reporting.  Research suggests that health care providers tend to under-report [...]